GB869511A - Improvements in or relating to steroids and the manufacture thereof - Google Patents
Improvements in or relating to steroids and the manufacture thereofInfo
- Publication number
- GB869511A GB869511A GB14103/59A GB1410359A GB869511A GB 869511 A GB869511 A GB 869511A GB 14103/59 A GB14103/59 A GB 14103/59A GB 1410359 A GB1410359 A GB 1410359A GB 869511 A GB869511 A GB 869511A
- Authority
- GB
- United Kingdom
- Prior art keywords
- methyl
- dihydroxy
- dione
- pregnadiene
- pregnene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
The invention comprises compounds having the formulae: wherein R is hydrogen or the acyl radical of a hydrocarbon carboxylic acid of from 1-12 carbon atoms, inclusive; R1 is b -hydroxy or keto; X111 is hydrogen, bromine, iodine, fluorine or chlorine; Ac is the acyl radical of a carboxylic acid; M is hydrogen or an alkali metal and the lower alkyl contains 1-8 carbon atoms inclusive, X is chlorine or bromine, and wherein the carbon atoms joined by the dotted line are single or double bonded; and a process for preparing such compounds by treating the 3-enmine of 11-keto-16-dehydroprogesterone with a Grignard reagent and hydrolysing to form 11-keto-16-methylprogesterone IV; reacting IV with oxalic acid diester and a base, and with halogen to obtain 2,21-dialkoxyoxalyl-2,21,21-trihalo 11-keto-16a methylprogesterone VI; rearranging with a strong base and removing the 2-halo group to produce 3,11-diketo-16a -methyl-4,17(20)-[cis]pregnadien-21-oic acid alkyl ester VIII; forming the 3-ketal from VIII, reducing with LiA1H4 and hydrolysing gives 11b ,21-dihydroxy-16a - methyl-4,17(20)- [cis]- pregnadiene-3-one XI; dehydrogenating with SeO2 followed by oxidative hydroxylation gives 11b , 17a - dihydroxy-21- acyloxy-16a - methyl-1,4pregnadiene-3, 20-dione XIV; hydrolysing or oxidising XIV gives the corresponding 21hydroxy and 11-keto compounds; treating XIV with a dehydrating agent and a source of hypohalous acid gives 11b ,17a -dihydroxy-9a -halo-21- acyloxy-16a - methyl-1, 4- pregnadiene3,20-dione XVII; reacting this compound with a base gives the 9,11-epoxy compound which with HF gives the corresponding 9a -fluoro11b -hydroxy compound. Illustrative products of the invention are 11b ,17a ,21-trihydroxy16a -methyl-4-pregnene-3,20-dione and the 21-acetate thereof, 9a -fluor-11b ,17a ,21-trihydroxy-16a -methyl-4-pregnene-3, 20-dione and the 21-acetate thereof, the corresponding 1,4-pregnadienes,3,11-diketo- 16a -methyl- 4,17(20) [cis]-pregnadiene-21-oic acid methyl ester, 11-keto-16a -methylprogesterone and the 3-pyrrolidyl enamine thereof, 11b ,21-dihydroxy-16a -methyl-4,17(20)-[cis]-pregnadiene-3-one and the 3-pyrrolidyl enamine thereof and 11b ,21-dihydroxy- 16a - methyl- 1,4,17(20) - [cis]-pregnatriene-3-one. Specifications 761,490, 771,344, 779,002 and 781,712 are referred to.ALSO:Pharmaceutical compositions comprise 11b , 17a ,21 - trihydroxy - 16a - methyl - 4 - pregnene-3,20 - dione, 16a - methyl - 17a ,21 - dihydroxy - 4 - pregnene - 3,11,20 - trione, 11b ,17a ,21 - trihydroxy - 16a - methyl - 1,4 - pregnadiene - 3,20-dione, 16a -methyl-17a ,21-dihydroxy-1,4-pregnadiene - 3,11,20 - trione, 9a - fluoro - 11b ,17a , 21 - trihydroxy - 16a - methyl - 4 - pregnene - 3,20 - dione, 9a - fluoro - 16a - methyl - 17a ,21 - dihydroxy - 4 - pregnene - 3,11,20 - trione, 9a -fluoro - 11b ,17a ,21 - trihydroxy - 16a - methyl - 1,4 - pregnadiene - 3,20 - dione, 9a - fluoro - 16a - methyl - 17a ,21 - dihydroxy - 1,4 - pregnadiene - 3,11,20-dione and their 21-esters incorporated in an inert ointment, cream, lotion or spray. In addition, antibiotics, e.g. penicillins, neomycin, tetracycline, chloramphenicol and novobiocin, may be present. Specification 761,490, 771,344, 779,002 and 781,712 are referred to.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US869511XA | 1958-05-26 | 1958-05-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
GB869511A true GB869511A (en) | 1961-05-31 |
Family
ID=22201934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB14103/59A Expired GB869511A (en) | 1958-05-26 | 1959-04-24 | Improvements in or relating to steroids and the manufacture thereof |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB869511A (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101168555B (en) * | 2006-10-27 | 2011-05-04 | 天津药业研究院有限公司 | Preparation of medicine and derivative thereof |
US8178679B2 (en) | 2007-11-28 | 2012-05-15 | Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors |
US8242177B2 (en) | 2005-05-20 | 2012-08-14 | Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor |
US8283342B2 (en) | 2007-02-09 | 2012-10-09 | Almirall S.A. | Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor |
EP2556083A2 (en) * | 2010-04-05 | 2013-02-13 | Validus Biopharma, Inc. | Non-hormonal steroid modulators of nf- kappa b for treatment of disease |
US8507670B2 (en) | 2006-08-22 | 2013-08-13 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
US8524908B2 (en) | 2009-03-12 | 2013-09-03 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
US8563731B2 (en) | 2008-12-22 | 2013-10-22 | Almirall, S.A. | Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor |
US9108918B2 (en) | 2011-10-07 | 2015-08-18 | Almirall, S.A. | Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate |
US9346759B2 (en) | 2012-03-20 | 2016-05-24 | Almirall, S.A. | Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor |
-
1959
- 1959-04-24 GB GB14103/59A patent/GB869511A/en not_active Expired
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8242177B2 (en) | 2005-05-20 | 2012-08-14 | Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor |
US8420669B2 (en) | 2005-05-20 | 2013-04-16 | Laboratories Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the BETA2 adrenergic receptor |
US8507670B2 (en) | 2006-08-22 | 2013-08-13 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
US8846910B2 (en) | 2006-08-22 | 2014-09-30 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
US8816073B2 (en) | 2006-08-22 | 2014-08-26 | Ranbaxy Laboratories Limited | Matrix metalloproteinase inhibitors |
CN101168555B (en) * | 2006-10-27 | 2011-05-04 | 天津药业研究院有限公司 | Preparation of medicine and derivative thereof |
US8283342B2 (en) | 2007-02-09 | 2012-10-09 | Almirall S.A. | Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor |
US8178679B2 (en) | 2007-11-28 | 2012-05-15 | Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptors |
US8563731B2 (en) | 2008-12-22 | 2013-10-22 | Almirall, S.A. | Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor |
US8524908B2 (en) | 2009-03-12 | 2013-09-03 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
EP2556083A4 (en) * | 2010-04-05 | 2013-12-04 | Validus Biopharma Inc | Non-hormonal steroid modulators of nf- kappa b for treatment of disease |
EP2556083A2 (en) * | 2010-04-05 | 2013-02-13 | Validus Biopharma, Inc. | Non-hormonal steroid modulators of nf- kappa b for treatment of disease |
US10000525B2 (en) | 2010-04-05 | 2018-06-19 | Reveragen Biopharma, Inc. | Non-hormonal steroid modulators of NF-κB for treatment of disease |
US9108918B2 (en) | 2011-10-07 | 2015-08-18 | Almirall, S.A. | Process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one via a novel intermediate |
US9346759B2 (en) | 2012-03-20 | 2016-05-24 | Almirall, S.A. | Polymorphic crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one, heminapadisytlate as agonist of the β2 adrenergic receptor |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3152154A (en) | 17-monoesters of 17alpha, 21-dihydroxy steroids and process for the preparation thereof | |
US2882282A (en) | Method of producing 3-keto-delta4, 6-steroid compounds from 3-keto a-ring saturated 6-dihydro steroid compounds | |
GB869511A (en) | Improvements in or relating to steroids and the manufacture thereof | |
Fried et al. | Synthesis and biological activity of 1-and 6-dehydro-9α-halocorticoids | |
GB902294A (en) | Improvements in or relating to steroids and the manufacture thereof | |
US2865935A (en) | 2-methyl steroids and process | |
US3681410A (en) | Process for preparing 17{60 -hydroxy-20-keto and 17{60 ,21-dihydroxy-20-keto pregnanes and derivatives and intermediates thereof | |
US2838496A (en) | 6-fluoro steroids and process for preparing same | |
US2934546A (en) | 6 alpha-fluoro steroids | |
US3056807A (en) | Process for the preparation of fluorosteroids | |
GB928302A (en) | í¸-pregnene compounds | |
US3637670A (en) | Intermediates and process for preparing useful 17alpha-hydroxy-20-keto and 17alpha 21-dihydroxy-20-keto pregnanes and derivatives thereof | |
US3169133A (en) | 3alpha-fluoroandrostanes and 15beta-fluorogesterone | |
US2899448A (en) | Certificate of correction | |
GB898291A (en) | Improvements in or relating to steroids and the manufacture thereof | |
US3053858A (en) | 10-fluoro-19-nor steroids | |
US2935511A (en) | Process of preparing 11 beta-hydroxy steroids | |
GB903049A (en) | Steroid compounds, preparation thereof and compositions thereof | |
US3370072A (en) | 17alpha-dihalomethyl corticoids and process for their preparation | |
US3519619A (en) | 16-alkylidene pregnanes and process for their manufacture | |
US3538131A (en) | 16alpha-methyl-6alpha-fluoro derivatives of reichstein substance s | |
US3415851A (en) | Method for the manufacture of steroidal delta-1,4-dieneones and new product obtainedthereby | |
US3005834A (en) | Dehydration of nuclear hydroxylated steroids | |
US2888468A (en) | Process for the production of delta5-3-keto and delta4-3-keto steroids | |
US3205226A (en) | 19-nor-5(10)-dehydro steroids and methods for their manufacture |